TNFRSF7/CD27 Rabbit Monoclonal Antibody (Clone RM501)

CD27, also known as tumor necrosis factor receptor superfamily receptor 7 (TNFRSF7), is a type I transmembrane glycoprotein with roles in T cell-mediated immunity.^1,2 It is composed of an extracellular domain containing three cysteine-rich domains (CRDs), a transmembrane domain, and a short cytoplasmic domain that facilitates intracellular signaling.¹ CD27 is expressed on a broad range of lymphocytes, including natural killer (NK), B, and T cells, with T cell CD27 expression increasing upon T cell receptor stimulation.³ Binding of homotrimeric CD70 to CD27 on antigen-primed T cells induces NF-kB and MAPK signaling through TNF receptor-associated factors (TRAFs) and, when the T cell is stimulated by other factors, induces PI3K signaling to induce the co-stimulation and expansion of naïve CD4⁺ and CD8⁺ T cells.^4,5 Knockout of CD27 reduces thymic development of regulatory T cell (Treg) precursors and enhances apoptosis of mature Tregs in mice. Levels of CD27-expressing plasma cells are increased in the periphery and positively correlate with the disease activity index and serum levels of anti-dsDNA autoantibodies in patients with systemic lupus erythematosus (SLE).⁶ Cayman’s TNFRSF7/CD27 Rabbit Monoclonal Antibody (Clone RM501) can be used for immunohistochemistry (IHC) and Western blot (WB) applications.

WARNING This product is not for human or veterinary use.

1. Buchan, S.L., Rogel, A., and Al-Shamkhani, A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood 131(1), 39-48 (2018).

2. Grant, E.J., Nüssing, S., Sant, S., et al. The role of CD27 in anti-viral T-cell immunity. Curr. Opin. Virol. 22, 77-88 (2017).

3. Hendriks, J., Gravestein, L.A., Tesselaar, K., et al. CD27 is required for generation and long-term maintenance of T cell immunity. Nat. Immunol. 1(5), 433-440 (2000).

4. Wyzgol, A., Müller, N., Fick, A., et al. Trimer stabilization, oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J. Immunol. 183(3), 1851-1861 (2009).

5. Wajant, H. Therapeutic targeting of CD70 and CD27. Expert Opin. Ther. Targets 20(8), 959-973 (2016).

6. Han, B.K., Olsen, N.J., and Bottaro, A. The CD27-CD70 pathway and pathogenesis of autoimmune disease. Semin. Arthritis Rheum. 45(4), 496-501 (2016).